Population
Patients with chronic kidney disease and patients undergoing hemodialysis treatment
Design
Review
Authors
Loading...
Supports sympatholytic investigation in CKD hypertension; leaves open outcome benefit pending prospective trials.
Sympathetic hyperactivity is a key contributor to cardiovascular morbidity in CKD, suggesting a potential role for sympatholytic therapies that requires validation in prospective trials.
Peter Kotanko (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: